Phaseline

Companies › Anthos Therapeutics

Anthos Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Cardiovascular; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Abelacimab (MAA868)
Coagulation factor XI inhibitor
F11Phase 3Atrial Fibrillation (AF)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05712200Abelacimab (MAA868)Phase 3Atrial Fibrillation (AF)CardiovascularDec 2027
NCT04755283Abelacimab (MAA868)Phase 2Atrial Fibrillation (AF)CardiovascularDec 2028

Targets

F11 (1)

Companies with the same targets

Regeneron Pharmaceuticals Suzhou Alphamab Johnson & Johnson (Janssen) Sirnaomics

Companies built like this

CeleCor Therapeutics MedTrace Pharma SPH Qingdao Growful Pharmacetical Hanlim Pharm. Trust Bio-sonics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.